Press releases
STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce the appointment of Marguerite Hutchinson, J.D., as Chief Business Officer.
Read more
STORM’s first-in-class investigational drug STC-15 is the first clinical stage molecule specifically targeting an RNA methyltransferase. STC-15 reshapes the tumour microenvironment and activates anti-tumour immunity.
Read more
STORM’s lead programme is the first RNA methyltransferase inhibitor to enter clinical development.
Read more
Pre-clinical data strongly supports progression of a METTL3 inhibitor in an immuno-oncology setting. STC-15 is the first molecule specifically targeting METTL3 to enter clinical development.
Read more
Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models. STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors
Read more